103 research outputs found
Circulating Extracellular Vesicles in Gynecological Tumors: Realities and Challenges
Although liquid biopsy can be considered a reality for the clinical management of some cancers, such as lung or colorectal cancer, it remains a promising field in gynecological tumors. In particular, circulating extracellular vesicles (cEVs) secreted by tumor cells represent a scarcely explored type of liquid biopsy in gynecological tumors. Importantly, these vesicles are responsible for key steps in tumor development and dissemination and are recognized as major players in cell-to-cell communication between the tumor and the microenvironment. However, limited work has been reported about the biologic effects and clinical value of EVs in gynecological tumors. Therefore, here we review the promising but already relatively limited data on the role of circulating EVs in promoting gynecological tumor spread and also their value as non-invasive biomarkers to improve the management of these type of tumors
Inhibition of α(1,6)fucosyltransferase: effects on cell proliferation, migration, and adhesion in an SW480/SW620 syngeneic colorectal cancer model
The present study explored the impact of inhibiting α(1,6)fucosylation (core fucosylation) on the functional phenotype of a cellular model of colorectal cancer (CRC) malignization formed by the syngeneic SW480 and SW620 CRC lines. Expression of the FUT8 gene encoding α(1,6)fucosyltransferase was inhibited in tumor line SW480 by a combination of shRNA-based antisense knockdown and Lens culinaris agglutinin (LCA) selection. LCA-resistant clones were subsequently assayed in vitro for proliferation, migration, and adhesion. The α(1,6)FT-inhibited SW480 cells showed enhanced proliferation in adherent conditions, unlike their α(1,6)FT-depleted SW620 counterparts, which displayed reduced proliferation. Under non-adherent conditions, α(1,6)FT-inhibited SW480 cells also showed greater growth capacity than their respective non-targeted control (NTC) cells. However, cell migration decreased in SW480 after FUT8 knockdown, while adhesion to EA.hy926 cells was significantly enhanced. The reported results indicate that the FUT8 knockdown strategy with subsequent selection for LCA-resistant clones was effective in greatly reducing α(1,6)FT expression in SW480 and SW620 CRC lines. In addition, α(1,6)FT impairment affected the proliferation, migration, and adhesion of α(1,6)FT-deficient clones SW480 and SW620 in a tumor stage-dependent manner, suggesting that core fucosylation has a dynamic role in the evolution of CRC.Ministerio de Educación y Ciencia | Ref. AP-FPU12/03662Xunta de Galicia | Ref. GRC 2014/019Xunta de Galicia | Ref. CN 2011/02
Core fucosylation mediated by the FucT-8 enzyme affects TRAIL-induced apoptosis and sensitivity to chemotherapy in human SW480 and SW620 colorectal cancer cells
Epithelial cells can undergo apoptosis by manipulating the balance between pro-survival and apoptotic signals. In this work, we show that TRAIL-induced apoptosis can be differentially regulated by the expression of α(1,6)fucosyltransferase (FucT-8), the only enzyme in mammals that transfers the α(1,6)fucose residue to the pentasaccharide core of complex N-glycans. Specifically, in the cellular model of colorectal cancer (CRC) progression formed using the human syngeneic lines SW480 and SW620, knockdown of the FucT-8-encoding FUT8 gene significantly enhanced TRAIL-induced apoptosis in SW480 cells. However, FUT8 repression did not affect SW620 cells, which suggests that core fucosylation differentiates TRAIL-sensitive premetastatic SW480 cells from TRAIL-resistant metastatic SW620 cells. In this regard, we provide evidence that phosphorylation of ERK1/2 kinases can dynamically regulate TRAIL-dependent apoptosis and that core fucosylation can control the ERK/MAPK pro-survival pathway in which SW480 and SW620 cells participate. Moreover, the depletion of core fucosylation sensitises primary tumour SW480 cells to the combination of TRAIL and low doses of 5-FU, oxaliplatin, irinotecan, or mitomycin C. In contrast, a combination of TRAIL and oxaliplatin, irinotecan, or bevacizumab reinforces resistance of FUT8-knockdown metastatic SW620 cells to apoptosis. Consequently, FucT-8 could be a plausible target for increasing apoptosis and drug response in early CRC.Ministerio de Educación y Ciencia | Ref. AP-FPU12/03662Xunta de Galicia | Ref. Contrato-Programa de Consolidación de Unidades de Investigación Competitivas, CN 2011/024Xunta de Galicia | Ref. Contrato-Programa de Consolidación de Grupos de Referencia Competitiva, GRC 2014/01
Circulating microRNAs as promising biomarkers in colorectal cancer
Colorectal cancer (CRC) is one of the most common cancers and a leading cause of
cancer-related deaths worldwide. Despite numerous advances in therapeutic approaches, this cancer
has a poor prognosis when it is diagnosed at late stages. Therefore, the scientific e ort is nowadays
directed towards the development of new non-invasive and dynamic biomarkers to improve the
survival expectancy of CRC patients. In this sense, deregulated expression of many miRNAs has been
shown to play an important role for CRC carcinogenesis and dissemination. Noticeably, an increasing
number of studies highlight that circulating miRNAs, including those traveling inside exosomes or
those released by tumor cells into circulation, constitute a promising tool for early detection, prognosis
and therapy selection of CRC. Therefore, in this review we focus on the clinical potential of blood
circulating miRNAs as emerging biomarkers with high value to improve the clinical management of
CRC patients, providing a deep and complete perspective of the realities and challenges to translate
these biomarkers to the clinical contextThis study was supported by the Consellería de Cultura, Educación e Ordenación Universitaria da
Xunta de Galicia (Spain), grant number: ED431B2017/029S
EGFR-Based Immunoisolation as a Recovery Target for Low-EpCAM CTC Subpopulation
Circulating tumour cells (CTCs) play a key role in the metastasis process, as they are responsible for micrometastasis and are a valuable tool for monitoring patients in real-time. Moreover, efforts to develop new strategies for CTCs isolation and characterisation, and the translation of CTCs into clinical practice needs to overcome the limitation associated with the sole use of Epithelial Cell Adhesion Molecule (EpCAM) expression to purify this tumour cell subpopulation. CTCs are rare events in the blood of patients and are believed to represent the epithelial population from a primary tumour of epithelial origin, thus EpCAM immunoisolation is considered an appropriate strategy. The controversy stems from the impact that the more aggressive mesenchymal tumour phenotypes might have on the whole CTC population. In this work, we first characterised a panel of cell lines representative of tumour heterogeneity, confirming the existence of tumour cell subpopulations with restricted epithelial features and supporting the limitations of EpCAM-based technologies. We next developed customised polystyrene magnetic beads coated with antibodies to efficiently isolate the phenotypically different subpopulations of CTCs from the peripheral blood mononuclear cells (PBMCs) of patients with metastatic cancer. Besides EpCAM, we propose Epidermal Growth Factor Receptor (EGFR) as an additional isolation marker for efficient CTCs detection.This work was supported by Axencia Galega de Innovación (Xunta de Galicia) and InveNNta (Innovation in Nanomedicine), cofinanced by the European Union (EU) through the Operational Programme for Cross-border Cooperation: Spain-Portugal (POCTEP 2007-2013), and European Regional Development Fund (ERDF)S
Cancer Salivary Biomarkers for Tumours Distant to the Oral Cavity
The analysis of saliva as a diagnostic approach for systemic diseases was proposed just
two decades ago, but recently great interest in the field has emerged because of its revolutionary
potential as a liquid biopsy and its usefulness as a non-invasive sampling method. Multiple molecules
isolated in saliva have been proposed as cancer biomarkers for diagnosis, prognosis, drug monitoring
and pharmacogenetic studies. In this review, we focus on the current status of the salivary diagnostic
biomarkers for different cancers distant to the oral cavity, noting their potential use in the clinic and
their applicability in personalising cancer therapiesS
Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part I: A Diagnostic Accuracy Meta-Analysis
DNA hypermethylation is an important epigenetic mechanism for gene expression inactivation in head and neck cancer (HNC). Saliva has emerged as a novel liquid biopsy representing a potential source of biomarkers. We performed a comprehensive meta-analysis to evaluate the overall diagnostic accuracy of salivary DNA methylation for detecting HNC. PubMed EMBASE, Web of Science, LILACS, and the Cochrane Library were searched. Study quality was assessed by the Quality Assessment for Studies of Diagnostic Accuracy-2, and sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (dOR), and their corresponding 95% confidence intervals (CIs) were calculated using a bivariate random-effect meta-analysis model. Meta-regression and subgroup analyses were performed to assess heterogeneity. Eighty-four study units from 18 articles with 8368 subjects were included. The pooled sensitivity and specificity of salivary DNA methylation were 0.39 and 0.87, respectively, while PLR and NLR were 3.68 and 0.63, respectively. The overall area under the curve (AUC) was 0.81 and the dOR was 8.34. The combination of methylated genes showed higher diagnostic accuracy (AUC, 0.92 and dOR, 36.97) than individual gene analysis (AUC, 0.77 and dOR, 6.02). These findings provide evidence regarding the potential clinical application of salivary DNA methylation for HNC diagnosisThis work was co-funded by the Instituto de Salud Carlos III (ISCIII) (PI20/01449) and the European Regional Development Fund (FEDER). A.D.-L. is funded by a “Juan Rodés” contract from ISCIII (JR17/00016). L.M.-R. is funded by a “Miguel Servet” contract from ISCIII (CP20/00129)S
Cell-Free microRNAs as potential oral cancer biomarkers: from diagnosis to therapy
Oral cavity cancer is the most frequent malignancy of the head and neck. Unfortunately,
despite educational interventions for prevention and early diagnosis, oral cancer patients are often
diagnosed in advanced stages associated with poor prognosis and life expectancy. Therefore, there is
an urgent need to find noninvasive biomarkers to improve early detection of this tumor. Liquid biopsy
has emerged as a valuable tool in medical oncology which provides new horizons for improving
clinical decision making. Notably, cell-free microRNAs (miRNAs), a class of short non-coding RNAs,
are emerging as novel noninvasive cancer biomarkers. Here, we provide an overview of the potential
clinical application of cell-free miRNAs as diagnostic, prognostic, and therapeutic biomarkers in
oral cancerS
ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas
Myometrial infiltration represents a main clinical determinant of endometrial carcinomas (EC) presenting as aggressive high-grade deeply invasive neoplasms, substantially associated with risk of recurrence and death. The up-regulation of ETV5 transcription factor linked to the promotion of epithelial to mesenchymal transition is considered as a basic mechanism underlying the initial steps of EC invasion. In this work, we aimed to investigate the transcription program of tumor invasion regulated by ETV5. We performed a comparative Chip-on-chip analysis at invasive front and superficial area of human EC. ETV5 specific binding to promoter regions of genes related to cellular migration, adhesion and invasion at deep invasion tumor areas highlighted the relevance of neural networks associated with cellular plasticity. Interestingly, brain-derived neurotrophic factor (BDNF) demonstrated a principal role orchestrating ETV5-mediated epithelial-to-mesenchymal transition in endometrial cancer. Impairment of the BDNF/tropomyosin-related kinase B (TrkB)/extracellular signal-regulated kinase axis in endometrial cancer cell lines reversed the aggressive and invasive phenotype promoted by the up-regulation of ETV5 at the invasive front of EC. Likewise, BDNF directly impacted on the efficiency of ETV5 promoted metastasis in a mice model of endometrial distant dissemination. These results translate the recognized role of BDNF/TrkB on neural plasticity into a relevant cancer metastasis event; suggest common mechanisms shared by neural development and tumor invasion; and offer new therapeutic opportunities specifically directed against disseminated disease in endometrial cancer
Response to commentary by Lu and Wang on: "Salivary biomarkers for cancer diagnosis: a meta-analysis"
- …